Table 2.

Results of palliative mono- and poly-chemotherapy to advanced salivary gland cancers

	VNB [32]	VNB/Cisplatin	Cisplatin [33]	Paclitaxel [34]	Mitoxantrone/Cisplatin [35]	Cyclo-phosphamide/Doxorubicin/Cisplatin CAP [36]	Adriamycin/cis-Platinum/Cyclo-phosphamide [37]	Docetaxel [38]
CR	0	3(19%)	3(12%)	0(0%)	0(0%)	3(23%)	3(60%)	2(50%)
PR	4(20%)	4(25%)	1(4%)	8(17·8%)	2(14·3%)	3(23%)	2(40%)	2(50%)
NC	9(45%)	6(37·5%)		15(33·3%)	9(64·3%)
PD	7(35%)	3(19%)		20(44·4%)	3(21·4%)
NE				2(4·4%)
Patients	20	16	25	45	14	13	5	4

VNB: vinorelbine; CR: complete response; PR: partial response; NC: no change (stable disease); PD: progressive disease; NE: not evaluable